Trials / Unknown
UnknownNCT02903524
Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer
The Efficacy and Safety of Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared to Pirarubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer ：a Randomised Multicentre, Open-label Trial
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Hebei Medical University Fourth Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy and safety of Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared to Pirarubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxorubicin Hydrochloride Liposome injection and cyclophosphamide | |
| DRUG | pirarubicin and cyclophosphamide |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-09-01
- Completion
- 2018-12-01
- First posted
- 2016-09-16
- Last updated
- 2016-09-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02903524. Inclusion in this directory is not an endorsement.